Oppenheimer Downgrades Fate Therapeutics to Perform
Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Goldman Sachs Initiates Coverage On Fate Therapeutics with Sell Rating, Announces Price Target of $10
Goldman Sachs analyst Andrea Tan initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Sell rating and announces Price Target of $10.
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session
Gainers
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
Fate Therapeutics Announces Exercise By ONO Pharmaceutical Of Option To HER2-Targeted CAR T-Cell Product Candidate For Solid Tumors
Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models
Fate and ONO to Jointly Develop and
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $35
Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $45 to $35.
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers
Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.